Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 20471940 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Chin YR, Toker A (2010) The actin-bundling protein palladin is an Akt1-specific substrate that regulates breast cancer cell migration. Mol Cell 38, 333-44 20471940
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

S473-p - Akt1 (human)
Orthologous residues
Akt1 (human): S473‑p, Akt1 (mouse): S473‑p, Akt1 (rat): S473‑p, Akt1 (fruit fly): S586‑p, Akt1 (cow): S473‑p
Characterization
 Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
 Disease tissue studied:  breast cancer
 Relevant cell lines - cell types - tissues:  BT-549 (breast cell), HeLa (cervical), MCF-10A (breast cell), SKBr3 (breast cell)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IGF-1 increase
wortmannin IGF-1 inhibit treatment-induced increase
Akt-I-1,2 IGF-1 inhibit treatment-induced increase
EGF increase
wortmannin EGF inhibit treatment-induced increase
Akt-I-1,2 EGF inhibit treatment-induced increase

S1118-p - palladin (human)
Orthologous residues
palladin (human): S1118‑p, palladin iso6 (human): , palladin (mouse): S1143‑p, palladin (rat): S1030‑p
Characterization
 Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
 Disease tissue studied:  breast cancer
 Relevant cell lines - cell types - tissues:  BT-549 (breast cell), HeLa (cervical), MCF-10A (breast cell), SKBr3 (breast cell)
 Cellular systems studied:  cell lines
 Species studied:  human
 Enzymes shown to modify site in vitro
Type Enzyme
KINASE Akt1 (human)
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE Akt1 (human) activation of upstream enzyme, modification site within consensus motif, siRNA inhibition of enzyme, mutation in upstream enzyme recognition motif, pharmacological inhibitor of upstream enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IGF-1 increase
wortmannin IGF-1 inhibit treatment-induced increase
Akt-I-1,2 IGF-1 inhibit treatment-induced increase
EGF increase
wortmannin EGF inhibit treatment-induced increase
Akt-I-1,2 EGF inhibit treatment-induced increase
Downstream Regulation
 Effect of modification (process):  cell motility, altered, cytoskeletal reorganization


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.